We conducted a phase 2–3 double-blind trial to assess the efficacy and safety of nirmatrelvir–ritonavir in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact ...
A recent shot of the COVID-19 vaccine doubled survival time in glioblastoma patients who had undergone tumor biopsy or ...
ABC News on MSN
COVID-19 facts, fiction and a new post-exposure treatment
Sponsored by Shionogi, maker of XOCOVA, Dr. Aimish Adolllja discusses COVID-19 myths, current virus activity and a new ...
For one in 10 people who catch the flu, COVID-19 or other respiratory viruses, the symptoms can turn life-threatening.
Oral Paxlovid (nirmatrelvir-ritonavir) is highly effective at preventing hospitalization and death from COVID-19, yet it has been remarkably underused, even by patients at highest risk from COVID-19, ...
Despite frequent mentions of scientific evidence, U.S. media largely ignored uncertainties and relied on non-experts, fueling public confusion during the early COVID-19 crisis. In a recent study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results